Skip to main content
Premium Trial:

Request an Annual Quote

ArcherDx, HeliTec Partner on Cancer Dx Development

NEW YORK (GenomeWeb) – ArcherDx has partnered with HeliTec on the development of next-generation sequencing-based cancer diagnostics for the Chinese market, the companies announced today.

Under the terms of the deal, the companies will codevelop and cross-license certain NGS technologies with the goal of registering oncology diagnostic kits with the China Food and Drug Administration. In addition, all of ArcherDx's NGS assays — including its FusionPlex RNA assays, VariantPlex DNA assays, Reveal ctDNA 28 kit, and Immunoverse T-cell receptor kit — are now available from Shenzhen-based HeliTec.

The companies noted that HeliTec is also currently evaluating the Reveal assay to identify oncogenic mutations in liquid biopsies in a recently announced large-scale clinical study.

Additional terms of the deal were not disclosed.

"We are pleased to work with Archer to co-develop cutting-edge, NGS-based diagnostic assays in China, particularly on those cancer types predominant in Asian populations," HeliTec CEO Dongbin Zhou said in a statement.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.